Physician profile
David Ettinger
NPI 1598096018
$15,569.61
in general payments reported to CMS, 2019-2025
29 companies · $3,914 in 2025
The $3,914 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,343 · 2022: $3,200 · 2023: $2,959 · 2024: $4,154 · 2025: $3,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,008.25 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,847.77 | 2021-2025 | |
| Janssen Biotech, INC. | $2,302.17 | 2021-2025 | Tremfya, Remicade, Stelara |
| Genzyme Corporation | $1,064.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,040.95 | 2021-2025 | |
| Ucb, INC. | $906.19 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $899.13 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $850.02 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $824.93 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $791.67 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $632.02 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $561.03 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $373.19 | 2023-2024 | Vtama |
| Amgen INC. | $370.52 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $345.60 | 2021-2025 | Opzelura |
| Kerecis Limited | $327.38 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $298.32 | 2023-2025 | Zoryve |
| Medimetriks Pharmaceuticals, INC. | $294.39 | 2022-2023 | Tovet (Emollient Formulation) |
| Galderma Laboratories, L.P. | $232.66 | 2021-2025 | Nemluvio, Aklief |
| Journey Medical Corporation | $162.97 | 2022 | |
| Organon LLC | $74.97 | 2024-2025 | Vtama |
| Hill Dermaceuticals, INC. | $71.33 | 2021 | |
| Organogenesis INC. | $66.42 | 2022-2023 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.00 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $41.99 | 2024 | Poteligeo |
| Krystal Biotech INC | $39.74 | 2023-2024 | Vyjuvek |
| Mayne Pharma Commercial LLC | $34.92 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.61 | 2021 | |
| Vyne Pharmaceuticals INC. | $22.77 | 2021 | |
| Epi Health, LLC | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ettinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.